

Screening and identification of endometrium proteins as novel potential biomarkers for repeated implantation failure

Chong Wang^{1,2}, Ying Feng¹, Wen-Jing Zhou¹, Zhao-Jun Cheng¹, Mei-Yan Jiang¹, Yan Zhou¹, Xiao-Yang Fei^{Corresp. 1}

¹ Hangzhou Women's Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, China

² Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China

Corresponding Author: Xiao-Yang Fei

Email address: feixy1962@163.com

Repeated implantation failure (RIF) patients are the bottleneck of clinical pregnancy rate for assisted reproductive technology, due to poor endometrial receptivity. We collected endometrial tissue at the window of implantation by hysteroscopybiopsy during September 2016 to December 2019, clinical data were collected as well. A total of 82 differentially expressed endometrium proteins were identified, including 55 up-regulated proteins (>1.50 -fold, $P<0.05$) and 27 down-regulated proteins (<0.67 -fold, $P<0.05$) by iTRAQ labeling coupled with 2D LC MS/MS technique. String analysis found interactions between these proteins which assembled in two bunches, ribosomal proteins and blood homeostasis proteins. In addition, the most significant enriched Gene Ontology terms were negative regulation of hydrolase activity, blood microparticle, and enzyme inhibitor activity. Verified results highlighted the corticosteroid binding globin as the specific protein of endometrial receptivity, representing low progesterone level. Our study provided experimental data to establish the objective indicator of endometrial receptivity, and also provided a new sight into the pathogenesis of RIF.

1 Screening and identification of endometrium proteins 2 as novel potential biomarkers for repeated 3 implantation failure

4

5 Chong Wang^{1,2}, Ying Feng¹, Wen-Jing Zhou¹, Zhao-Jun Cheng¹, Mei-Yan Jiang¹, Yan Zhou¹,
6 Xiao-Yang Fei^{1,*}

7

8 ¹ Reproductive Medicine Center, Hangzhou Women's Hospital (Hangzhou Maternity and Child
9 Health Care Hospital), Hangzhou 310008, P.R. China

10 ² Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine,
11 Hangzhou 310006, P.R. China

12

13 Corresponding Author:

14 Xiao-Yang Fei¹

15 No.369 Kunpeng Road, Shangcheng District, Hangzhou 310008, P.R. China.

16 Email address: feixy1962@163.com

17

18 Abstract

19 Repeated implantation failure (RIF) patients are the bottleneck of clinical pregnancy rate for
20 assisted reproductive technology, due to poor endometrial receptivity. We collected endometrial
21 tissue at the window of implantation by hysteroscopybiopsy during September 2016 to
22 December 2019, clinical data were collected as well. A total of 82 differentially expressed
23 endometrium proteins were identified, including 55 up-regulated proteins (>1.50-fold, $P<0.05$)
24 and 27 down-regulated proteins (<0.67-fold, $P<0.05$) by iTRAQ labeling coupled with 2D LC
25 MS/MS technique. String analysis found interactions between these proteins which assembled in
26 two bunches, ribosomal proteins and blood homeostasis proteins. In addition, the most
27 significant enriched Gene Ontology terms were negative regulation of hydrolase activity, blood
28 microparticle, and enzyme inhibitor activity. Verified results highlighted the corticosteroid
29 binding globin as the specific protein of endometrial receptivity, representing low progesterone
30 level. Our study provided experimental data to establish the objective indicator of endometrial
31 receptivity, and also provided a new sight into the pathogenesis of RIF.

32

33 Introduction

34 According to the World Health Organization, infertility prevalence was highest in South
35 Asia, Sub-Saharan Africa, North Africa/Middle East, and Central/Eastern Europe and Central
36 Asia (Mascarenhas et al., 2012). The infertility rate of China's childbearing age couples was 25%
37 (Zhou et al., 2018). Assisted reproductive technology (ART) is the best way to help infertility
38 patients to have children successfully at this stage, and the number of these patients increased
39 randomly (Kushnir et al., 2017).

40 In vitro fertilization and embryo transfer (IVF-ET) is the most common way of ART.
41 Although it can help some infertile women to get pregnant successfully, there were still some
42 patients who could not get pregnant even after multiple transplantations (2-6 times) of high-
43 quality embryos, whom were classified as repeated implantation failure (RIF) patients
44 (Margalioth et al., 2006). These patients are the bottleneck of clinical pregnancy rate of ART
45 technology. The two key factors for successful implantation are embryo quality and endometrial
46 receptivity. The embryo quality nowadays could be evaluated by several criteria. Meanwhile,
47 endometrial receptivity is defined as the period during which the endometrial epithelium acquires
48 functional, but transient, ovarian steroid-dependent status supportive to blastocyst acceptance
49 and implantation. This period was called window of implantation (WOI). The golden standard
50 for evaluating endometrial receptivity is the pinopodes in endometrial histology. However, it
51 changes from samples and menstrual cycles (Acosta et al., 2000). The ultrasound examination
52 was a noninvasive and inexpensive test widely used, which contained endometrial thickness,
53 endometrial type, endometrial volume, uterine artery and sub-endometrial blood flow. However,
54 this examination with strong subjectivity shows a little effect in predicting pregnancy rate with
55 single parameter. A number of studies have applied proteomic techniques to analyze human
56 endometrium crossing different cycle phases, sampled by either biopsy or curettage (Chen et al.,
57 2009; Yap et al., 2011). Former researchers (Yap et al., 2011) identified IL-11 regulated plasma
58 membrane proteins ANXA2, and the lipid-raft protein FLOT1 in human endometrial epithelial
59 cells in vitro in the receptive phase of the menstrual cycle.

60 In this study, differential WOI endometrium proteins were screened using iTRAQ labeling
61 coupled with 2D LC-MS/MS technique in order to find potential biomarkers for RIF patients.
62 Our study provided experimental data to establish the objective indicator of endometrial
63 receptivity, and also provided a new way to reveal the pathogenesis of RIF.

64

65 **Materials & Methods**

66 **Sample collection**

67 This study was approved by the Ethics Committee of the Faculty of Medicine (Hangzhou
68 Women's Hospital, China) (Approval Number: 2016001-10). Written informed consents were
69 obtained from all subjects before endometrium collection.

70 RIF was defined as failure of three or more cycles in which reasonably high-quality
71 embryos were transferred (Margalioth et al., 2006). The criteria of embryo quality were
72 determined as grade I and grade II were high-quality embryos (Gardner et al., 1998). The criteria
73 of blastocyst quality were also determined according to Gardner et al. (Gardner et al., 1998).
74 Blastocysts were considered high-quality if they had a grade 3 or 4 blastocoel, a grade A or B
75 inner cell mass, and a grade A or B trophectoderm on days 5 or 6. Fifty-two RIF cases and 135
76 pregnant cases undergoing IVF-ET treatment were collected in our hospital during September
77 2016 to December 2019. Data including age, follow-up outcomes, and clinical examination
78 findings were collated into databases. The endometrium tissue was collected at WOI by

79 hysteroscopybiopsy, each for 200~500 μg . We washed these tissues by saline immediately, then
80 froze in liquid nitrogen and stored until protein extraction.

81 **Endometrium protein extraction**

82 We randomly selected 2 cases of pregnant patients and 3 cases of RIF patients for
83 endometrial protein extraction. Protein extraction was performed using lysis buffer after grinded
84 the sample to powder in liquid nitrogen. Add PMSF with final concentration of 1mM and EDTA
85 with final concentration of 2mM, wait for 5 min, and then add DTT with final concentration of
86 10mM. Ice bath ultrasound for 5 min, the lysate was centrifuged at 15,000 g for 20 min. The
87 supernatant was precipitated with 5 times volume of acetone and incubated at 20 °C for 2 h and
88 then centrifuged at 15,000 g and 4 °C for 20 min. The precipitate was washed by chilled acetone,
89 incubated at 20 °C for 30 min and centrifuged again at 15,000 g and 4 °C for 20 min. The
90 washing was repeated two times. After airdried, the precipitate was re-dissolved with the lysis
91 buffer. After ice bath ultrasound for 5 min, centrifuged precipitate again at 15,000 g and 4 °C for
92 20 min. The supernatant was determined using a Bradford Protein Assay Kit to detect the protein
93 concentration.

94 **Protein digestion and iTRAQ-2D LC-MS/MS**

95 A total of 100 μg protein from each group was digested using trypsin (Promega, USA) at
96 1:50 trypsin-to-protein mass ratio at 37 °C for 16 h. Then peptides were reconstituted in 0.2M
97 TEAB and processed according to the manufacturer's protocol for 8-plex iTRAQ reagent (AB
98 SCIEX, Framingham, MA, USA). Three biological replicates of the RIF group were labeled with
99 113, 114 and 115 isobaric tags, respectively. The peptides with two biological replicates of
100 pregnant group were labeled with 116 and 117 isobaric tags, respectively.

101 The peptides mixtures were subjected to the first-dimensional fractionation procedure using
102 high pH reversed-phase chromatography column (Phenomenex, Gemini-NX 3u C18110A,
103 150*2.00mm). A total of 16 fractions were finally collected and dried for the following LC-MS
104 analysis. The lyophilized peptide fractions were re-suspended in 2% acetonitrile containing 0.1%
105 formic acid, and loaded into a C18 trap column (Acclaim PepMap 75 μm \times 150mm, C18, 3 μm ,
106 100A). The online Chromatography separation was per- formed on the nanoLC system (Dionex
107 Ultimate 3000 RSLCnano). The trapping and desalting procedures were carried out at a flow rate
108 of 3 $\mu\text{L}/\text{min}$ for 5 min with 100% solvent A (0.1% formic acid, 2% acet- onitrile and 98% water).
109 Then, Peptides were than eluted using 65 min gradient of buffer A (0.1% formic acid) to buffer
110 B (80% ACN containing 0.1% formic acid) at 300 nL/min. It was used on an analytical column
111 (Acclaim PepMap 75 μm \times 15 cm C18-CL, 3 μm 100 Å, Thermo160321). IDA (information-
112 dependent acquisition) mass spectrum technique was used to acquire tandem MS data on Q
113 Exactive system (Thermo Scientific) fitted with a Nanospray ion source. Data were acquired
114 using an ion spray voltage of 2.2 kV. MS spectra were acquired across the scan range of 350–
115 1800 m/z in a resolution of 70,000 using maximum injection time (60 ms) per spectrum. Twenty
116 most intense precursors per MS cycle were selected for fragmentation detected with 100 ms
117 maximum injection time. Tandem mass spectra were recorded in a resolution of 17,500 with

118 rolling collision energy on and iTRAQ reagent collision energy adjustment on. For accurate mass
119 measurements, the lock mass option was enabled. Dynamic exclusion was set for 10 s.

120 The MS/MS data were analyzed using IPeak and IQuant software to obtain the protein
121 identification and quantification (Wen et al., 2015; Wen et al., 2014), and NCBI *human* genome.
122 Only proteins identified at global FDR $\leq 1\%$ with ≥ 1 peptide were considered for protein lists
123 and further downstream analysis. To determine a differentially expressed protein, it must be
124 identified and quantified with at least 1 significant peptide and the p-values of proteins
125 quantitation should be less than 0.05 and fold change ≥ 1.5 .

126 **Bioinformatics analysis**

127 Functional annotation was performed using Gene Ontology (GO) database
128 (<http://www.geneontology.org>) including cellular component, molecular function, and biological
129 process. The differentially expressed protein–protein network was analyzed by STRING
130 software (<http://www.string-db.org/>). The Kyoto Encyclopedia of Genes and Genomes (KEGG)
131 database (<http://www.genome.jp/kegg/or> <http://www.kegg.jp/>) was used to predict the main
132 metabolic pathways (Kanehisa et al., 2007). We obtained the significantly enriched GO/pathway
133 items by hypergeometric test. The EggNOG database (<http://eggnogdb.embl.de>) was used for
134 pairwise orthology predictions, functional annotation and classification (Huerta-Cepas et al.,
135 2015).

136 **Westernblot analysis**

137 Tissues were lysed with 200 μ L of RIPA lysate (P0013B, Beyotime, Shanghai, China) plus
138 1mM PMSF at 4 °C for 30min. After centrifugation at 12,000 rpm for 10 min at 4 °C, the
139 supernatant was harvested and stored at -80 °C. BCA method was used to determine protein
140 concentration using BCA quantitative kit (P0009, Beyotime). Protein samples were subjected to
141 polyacrylamide gel electrophoresis, which were then transferred onto PVDF membrane
142 (IPVH00010, Millipore, Massachusetts, USA). The membrane was blocked by 5% skimmed
143 milk powder at room temperature for 2h. Then, the membrane was incubated with primary
144 antibodies including cortisol binding globulin (ab110648, abcam, Cambridge, United Kingdom),
145 Antithrombin III (ab126598, abcam) and GAPDH (60004-1-Ig, proteintech, Beijing, China) at 4
146 °C overnight, followed by goat anti-rabbit IgG-HRP (BK0027, BEST, Xian, China) and goat
147 anti-mouse anti-rabbit IgG-HRP (BK0023, BEST) secondary antibodies at room temperature for
148 1.5h. The blots were visualized using ECL Plus Luminous Kit (S17851, Yeasen, Shanghai,
149 China) with a gel imaging system, and the results were measured with Image J.

150 **Statistical analysis**

151 The parametric data were tested using the chi-square test for the composition ratios, paired
152 t-tests for means of two groups. *P* values <0.05 were considered statistically significant by the
153 SPSS software (Chicago, IL, version 18.0).

154

155 **Results**

156 **Clinical data analysis**

157 We recruited 52 RIF cases and 135 pregnant cases undergoing IVF-ET treatment during
158 September 2016 to December 2019. Data including age, follow-up outcomes, and clinical
159 examination findings were collated into databases. Considering elder age could affects the
160 pregnancy rate, a total of 40 subjects with RIF, aged under 40 years old, and 80 paired subjects
161 with pregnancy were finally analyzed. There were no significant differences between RIF
162 patients and pregnant controls in general and clinical data ($P>0.05$, Table 1).

163 **Endometrial proteomics results**

164 We identified a total of 6,102 proteins through iTRAQ-2D LC-MS/MS. Among the 6,102
165 identified proteins, a total of 5,840 had GO annotations, a proportion of 95.71% of all proteins; a
166 total of 5,504 had KEGG annotations, a proportion of 90.20% of all proteins; finally, a total of
167 6,097 had EggNOG annotations, a proportion of 99.92% of all proteins.

168 We performed quality control on the quantitative results through volcano maps and the
169 distributions of Coefficient of Variation. The hierarchical clustering provided a visualized mode
170 to display the clustering patterns of the different expressed proteins between the groups (Fig. 1).
171 Further screening revealed 82 differentially expressed proteins in RIF patients compared with
172 pregnant controls, including 55 up-regulated proteins (>1.50 -fold, $P<0.05$) and 27 down-
173 regulated proteins (<0.67 -fold, $P<0.05$) (Table 2).

174 **Bioinformatics analysis results**

175 Gene Ontology analysis of differentially expressed proteins revealed that most of the
176 proteins were involved in the response to stimulus (42 proteins), extracellular region (35
177 proteins), and structural molecule activity (10 proteins) (Fig. 2A). The most significant enriched
178 GOs were negative regulation of hydrolase activity (SPB6, APOA1, GMIP, THBG, CBG,
179 ANT3, and FETUA), blood microparticle (VTDB, IGHG4, APOA1, A1AG2, FETUA, ANT3,
180 and A1AG1), and enzyme inhibitor activity (ANT3, FETUA, CBG, ASPN, SPB6, THBG, and
181 APOA1) through hypergeometric testing (Figure 2B). Among them, ANT3, FETUA, and
182 APOA1 repeated three times, while CBG and THBG repeated two times. The molecular function
183 of these repeated proteins is serine-type endopeptidase inhibitor activity (Fig. 2C). Furthermore,
184 String analysis found interactions between these proteins (Fig. 2D) which assembled in two
185 bunches, ribosomal proteins and blood homeostasis proteins.

186 In addition, the KEGG pathway mapping revealed some significant pathways: immune
187 system (7 proteins) and translation (5 proteins) (Fig. 3A), enriched in primary immunodeficiency
188 (Fig. 3B). Finally, we analyzed through the EggNOG database that the differential proteins
189 associated with RIF are mostly clustered in classifications such as posttranslational modification,
190 protein turnover, chaperones (22 proteins), translation, ribosomal structure and biogenesis (8
191 proteins), and carbohydrate transport and metabolism (6 proteins) (Fig. 3C).

192 **Westernblot results**

193 We verified endometrium ATIII and CBG level by western blot, finding significant higher
194 level of CBG in RIF patients (Fig. 4). Furthermore, a significant difference in CBG was found
195 using grayscale detection by Image J ($P=0.003$).

196

197 Discussion

198 After more than 40 years, IVF technology has made rapid progress. However, the clinical
199 pregnancy rate remained around 33.8-42.7% (European IVF-Monitoring Consortium (EIM) for
200 the European Society of Human Reproduction and Embryology (ESHRE) et al., 2016; Sunderam
201 et al., 2019). After the implementation of blastocyst transplantation, the clinical pregnancy rate
202 increased to 60.4% (Ozgun et al., 2018). One of the key factors affecting the pregnancy rate of
203 IVF is the RIF, actually the poor endometrial receptivity is the main reason for the decrease of
204 pregnancy possibility in RIF patients. In our study, the endometrium of IVF-ET patients during
205 WOI was collected and divided into RIF group and pregnant controls group according to
206 pregnancy outcomes. Specific proteins related to endometrial receptivity were screened by
207 iTRAQ-2D LC-MS/MS.

208 Through iTRAQ-2D LC-MS/MS and bioinformatics analysis, 82 differential proteins were
209 obtained in the endometrium of RIF patients during the WOI, of which 55 were higher (> 1.50
210 times, $P < 0.05$) and 27 were lower (< 0.67 times, $P < 0.05$). The differential proteins obtained in
211 this study have also been identified in the early proteomic studies. Hannan et al. obtained 7
212 differential proteins of the uterine lavage fluid of pregnant/non-pregnant patients in the WOI by
213 2D-DiGE, furthermore, the antithrombin III was significantly increased in the non-pregnant
214 patients by immunohistochemistry (Hannan et al., 2010). In this study, the expression of
215 antithrombin III was 1.77 times as much as that in the pregnant group, which was similar to the
216 previous results, indicating the reliability of iTRAQ-2D LC-MS/MS. In addition, ribosomal
217 protein and plasmin are two kinds of proteins that have been screened both in this study and
218 previous studies (Domínguez et al., 2009).

219 Through gene annotation, Gene Ontology classification and hypergeometric test, the most
220 significant GO items were targeted in negative regulation of hydrolase activity, blood
221 microparticle, and enzyme inhibitor activity (Fig. 2B). The mostly repeated ANT3 (P01008),
222 FETUA (P02765), APOA1 (P02647), CBG (P08185), and THBG (P05543) assembled in serine-
223 type endopeptidase inhibitor activity in GO terms, indicating that these genes are the key genes
224 encoding endometrial receptive specific proteins. We have reason to believe that the molecular
225 function of these genes is the key target site of endometrial receptivity.

226 Combining known biological functions and literature review, we choose ANT3 and CBG as
227 candidate proteins for endometrial receptivity. Literature review found that the protein encoded
228 by ANT3 is antithrombin-III, a representative protein of prethrombotic state. The prethrombotic
229 state is one of the suspected causes of RIF (Qublan et al., 2006). Former study confirmed TGF-
230 $\beta 3$ is secreted by leiomyoma. And TGF- $\beta 3$ can significantly reduce the expression level of ATIII
231 in normal endometrial stromal cells, resulting in menorrhagia and reproductive dysfunction,
232 which shows that the disorder of coagulation function is one of the main reasons for RIF
233 (Sinclair et al., 2011). However, in our verification, ANT3 showed no significant difference in
234 RIF patients and pregnant controls. These might due to the consist of our RIF patients, in our
235 study, oviduct factors contain the most, not the leiomyoma.

236 CBG encodes corticosteroid-binding globulin, a multifaceted component in cortisol
237 delivery, acute and chronic inflammation, and metabolism and neurocognitive function (Meyer
238 et al., 2016). The increasing CBG level in pregnant period was also important at the materno-
239 fetal interface (Lei et al., 2015). In our study, we found significant higher level of CBG in RIF
240 patients (Fig. 4). Misao et al. suggested that the decrease of progesterone level in the blood can
241 lead to the increase of CBG expression in endometrium (Misao et al., 1995). However, in our
242 study, the lower level of serum progesterone was also found in RIF patients, but with no
243 significant difference (Table 1). We believed a larger sample of research was needed.

244 KEGG analysis and enrichment analysis showed that differential proteins were related to
245 the immune system and primary immunodeficiency (Fig. 3A, 3B). Therefore, the change of
246 immune response in RIF patients is self-evident. It has been shown that the abnormal and
247 functional defects of immune cells and molecules in endometrium during implantation can lead
248 to pregnancy failure (Liu et al., 2016). Therefore, we suspect that the change of endometrial
249 immune microenvironment could lead to RIF, which provides a new way for clinical assistant
250 treatment for RIF patients. In the present study, most proteins were annotated with
251 “posttranslational modification, protein turnover, chaperones” and “translation, ribosomal
252 structure and biogenesis function”, meaning that most proteins involved in modification after
253 translation, synthesis and degradation, folding, maintenance, intracellular transport, as well as
254 mRNA translation based on the EggNOG database except function unknown. The results of
255 KEGG and String analysis also confirmed that translation is impacted.

256

257 **Conclusions**

258 In general, our study screened the endometrium proteomics of RIF patients through iTRAQ-
259 2D LC-MS/MS, highlighted the corticostroid binding globin as the specific protein of
260 endometrial receptivity. Our results provide experimental data to establish the objective indicator
261 of endometrial receptivity, moreover, also give a new sight into the pathogenesis of RIF.

262

263 **Acknowledgements**

264 We thank for every patients included in our project.

265

266 **References**

- 267 **Acosta AA, Elberger L, Borghi M, Calamera JC, Chemes H, Doncel GF, Kliman H, Lema**
268 **B, Lustig L, Papier S. 2000.** Endometrial dating and Determination of the window of
269 implantation in healthy fertile women. *Fertility and sterility* **73**(4):788-798
- 270 **Chen JI, Hannan NJ, Mak Y, Nicholls PK, Zhang J, Rainczuk A, Stanton PG, Robertson**
271 **DM, Salamonsen LA, Stephens AN. 2009.** Proteomic characterization of midproliferative and
272 midsecretory human endometrium. *Journal of Proteome Research* **8**(4):2032-2044
- 273 **Domínguez F, Garrido-Gómez T, López JA, Camafeita E, Quiñonero A, Pellicer A, Simón**
274 **C. 2009.** Proteomic analysis of the human receptive versus non-receptive endometrium using

275 differential in-gel electrophoresis and MALDI-MS unveils stathmin 1 and annexin A2 as
276 differentially regulated. *Human Reproduction* **24**(10):2607-2617

277 **European IVF-Monitoring Consortium (EIM) for the European Society of Human**
278 **Reproduction and Embryology (ESHRE), Calhaz-Jorge C, de Geyter C, Kupka MS, de**
279 **Mouzon J, Erb K, Mocanu E, Motrenko T, Scaravelli G, Wyns C, Goossens V. 2016.**
280 Assisted reproductive technology in Europe, 2012: results generated from European registers by
281 ESHRE. *Human Reproduction* **31**(8):1638-1652

282 **Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, Hesla J. 1998.** A
283 prospective randomized trial of blastocyst culture and transfer in in vitro fertilization. *Human*
284 *Reproduction* **13**(12):3434-3440

285 **Hannan NJ, Stephens AN, Rainczuk A, Hincks C, Rombauts LJ, Salamonsen LA. 2010.**
286 2D-DiGE analysis of the human endometrial secretome reveals differences between receptive
287 and nonreceptive states in fertile and infertile women. *Journal of Proteome Research*
288 **9**(12):6256-6264

289 **Huerta-Cepas J, Szklarczyk D, Forslund K, Cook H, Heller D, Walter MC, Rattei T,**
290 **Mende DR, Sunagawa S, Kuhn M, Jensen LJ, von Mering C, Bork P. 2015.** eggnoG 4.5: a
291 hierarchical orthology framework with improved functional annotations for eukaryotic,
292 prokaryotic and viral sequences. *Nuclc Acids Research* **44**(D1):D286-293

293 **Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima**
294 **S, Okuda S, Tokimatsu T, Yamanishi Y. 2007.** KEGG for linking genomes to life and the
295 environment. *Nuclc Acids Research* **36**(suppl_1):D480-484

296 **Kushnir VA, Barad DH, Albertini DF, Darmon SK, Gleicher N. 2017.** Systematic review of
297 worldwide trends in assisted reproductive technology 2004-2013. *Reproductive Biology &*
298 *Endocrinology* **15**(1):6

299 **Lei JH, Yang X, Peng S, Li Y, Underhill C, Zhu C, Lin HY, Wang H, Hammond GL. 2015.**
300 Impact of corticosteroid-binding globulin deficiency on pregnancy and neonatal sex. *The Journal*
301 *of clinical endocrinology and metabolism* **100**(5): 1819-1827

302 **Liu L, Li FG, Yang M, Wang L, Chen Y, Wang L, Ji W, Fan JM. 2016.** Effect of pro-
303 inflammatory interleukin-17A on epithelial cell phenotype inversion in HK-2 cells in vitro.
304 *European cytokine network* **27**(2):27-33

305 **Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. 2006.** Investigation and treatment of
306 repeated implantation failure following IVF-ET. *Human Reproduction* **21**(12): 3036-3043

307 **Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. 2012.** National,
308 regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277
309 health surveys. *PLoS Medicine* **9**(12):e1001356

310 **Meyer EJ, Nenke MA, Rankin W, Lewis JG, Torpy DJ. 2016.** Corticosteroid-Binding
311 Globulin: A Review of Basic and Clinical Advances. *Hormone and Metabolic Research*
312 **48**(6):359-371

313 **Misao R, Nakanishi Y, Fujimoto J, Tamaya T. 1995.** Sex hormone-binding globulin and
314 corticosteroid-binding globulin mRNA levels in infertile women with luteal phase deficiency.

- 315 *Gynecological endocrinology : the official journal of the International Society of Gynecological*
316 *Endocrinology* **9**(3):195-200
- 317 **Ozgun K, Bulut H, Berkkanoglu M, Humaidan P, Coetzee K. 2018.** Artificial cryopreserved
318 embryo transfer cycle success depends on blastocyst developmental rate and progesterone
319 timing. *Reproductive Biomedicine Online* **36**(3):269-276
- 320 **Qublan HS, Eid SS, Ababneh HA, Amarin ZO, Smadi AZ, Al-Khafaji FF, Khader YS.**
321 **2006.** Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer
322 failure. *Human Reproduction* **21**(10):2694-2698
- 323 **Sinclair DC, Mastroyannis A, Taylor HS. 2011.** Leiomyoma simultaneously impair
324 endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of
325 TGF- β 3. *The Journal of clinical endocrinology and metabolism* **96**(2):412-421
- 326 **Sunderam S, Kissin DM, Zhang Y, Folger SG, Boulet SL, Warner L, Callaghan WM,**
327 **Barfield WD. 2019.** Assisted Reproductive Technology Surveillance - United States, 2016.
328 *Morbidity and mortality weekly report. Surveillance summaries* **68**(4):1-23
- 329 **Wen B, Du C, Li G, Ghali F, Jones AR, Käll L, Xu S, Zhou R, Ren Z, Feng Q, Xu X, Wang**
330 **J. 2015.** IPeak: an open source tool to combine results from multiple MS/MS search engines,
331 *Proteomics* **15**(17):2916-2920
- 332 **Wen B, Zhou R, Feng Q, Wang Q, Wang J, Liu S. 2014.** IQuant: an automated pipeline for
333 quantitative proteomics based upon isobaric tags. *Proteomics* **14**(20):2280-2285
- 334 **Yap J, Foo CF, Lee MY, Stanton PG, Dimitriadis E. 2011.** Proteomic analysis identifies
335 interleukin 11 regulated plasma membrane proteins in human endometrial epithelial cells in
336 vitro. *Reproductive Biology & Endocrinology* **9**(1):1-15
- 337 **Zhou Z, Zheng D, Wu H, Li R, Xu S, Kang Y, Cao Y, Chen X, Zhu Y, Xu S, Chen ZJ, Mol**
338 **BW, Qiao J. 2018.** Epidemiology of infertility in China: a population-based study. *BJOG: An*
339 *International Journal of Obstetrics & Gynaecology* **125**(4):432-441

Table 1 (on next page)

General and clinical data of repeated implantation failure patients (RIF) and pregnant controls.

All data are presented as the mean \pm SD. BMI: body mass index; AMH: anti-Mullerian hormone. ^aP-value between two groups using the paired t-test. ^bP-value between two groups using the chi-square test.

1 **Table 1** General and clinical data of repeated implantation failure patients (RIF) and pregnant
 2 controls.

	RIF group (n=40)	Control group (n=80)
Age (year) ^a	32.60±3.90	32.60±3.84
Infertility years (year) ^a	4.32±2.49	3.88±2.84
Infertility type (n) ^b		
Oviduct factors	20	33
Ovulation disorders	7	17
Oarium factors	3	9
Pelvic cavity factors	3	6
Male factors	3	7
Unknown causes	4	8
Endometrium thickness of transplant day (mm) ^a	11.00±3.66	12.17±1.04
High-quality rate of transplant embryo (%) ^b	87.75 (222/253)	90.91 (140/154)
BMI (kg/m ²) ^a	21.07±2.85	21.26±2.55
AMH (ng/mL) ^a	3.59±2.55	3.24±2.13
D-dimer (mg/L) ^a	269.24±151.46	272.64±171.38
Fibrinogen (G/L) ^a	2.49±0.65	2.54±0.72
Basal hormone level		
Follicle-stimulating hormone (IU/L) ^a	5.36±2.37	5.26±2.13
Estradiol (pg/mL) ^a	31.42±12.08	34.19±21.19
Progesterone (ng/mL) ^a	0.63±0.29	0.65±0.52
Prolactin (ng/mL) ^a	14.18±6.16	13.87±6.46
Luteinizing hormone (IU/L) ^a	3.19±1.82	2.93±2.15
Testosterone (ng/mL) ^a	0.53±0.43	0.46±0.26
Transformation day hormone level		
Estradiol (pg/mL) ^a	559.87±269.49	547.29±367.50
Progesterone (ng/mL) ^a	0.47±0.27	0.50±0.33

3 All data are presented as the mean ± SD. BMI: body mass index; AMH: anti-Mullerian hormone. ^aP-value
 4 between two groups using the paired t-test. ^bP-value between two groups using the chi-square test.

Table 2 (on next page)

Differentially expressed proteins and their expression levels quantified by iTRAQ-2DLC-MS/MS.

- 1 **Table 2** Differentially expressed proteins and their expression levels quantified by iTRAQ-
 2 2DLC-MS/MS.

Protein ID	Alternative name	Protein name	iTRAQ ratio
Increased in RIF/Controls			
Q9NYZ3	GTSE1	G2 and S phase-expressed protein 1	3.42
Q9UN19	DAPP1	Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide	3.38
Q5W111	SPRY7	SPRY domain-containing protein 7	3.11
P50225	ST1A1	Sulfotransferase 1A1	3.06
Q86UB9	TM135	Transmembrane protein 135	2.59
P05230	FGF1	Fibroblast growth factor 1	2.56
Q8NFU3	TSTD1	Thiosulfate:glutathionesulfurtransferase	2.49
Q8NDA2	HMCN2	Hemicentin-2	2.49
Q9H477	RBSK	Ribokinase	2.40
P15169	CBPN	Carboxypeptidase N catalytic chain	2.37
P02763	A1AG1	Alpha-1-acid glycoprotein 1	2.15
Q86VY4	TSYL5	Testis-specific Y-encoded-like protein 5	2.03
Q9UKJ8	ADA21	Disintegrin and metalloproteinase domain-containing protein 21	1.98
P02794	FRIH	Ferritin heavy chain	1.91
Q96RG2	PASK	PAS domain-containing serine/threonine-protein kinase	1.89
P08294	SODE	Extracellular superoxide dismutase [Cu-Zn]	1.88
P08582	TRFM	Melanotransferrin	1.87
Q9P2H3	IFT80	Intraflagellar transport protein 80 homolog	1.82
A0A0B4J1U7	IU7 HV601	Immunoglobulin heavy variable 6-1	1.81
P02765	FETUA	Alpha-2-HS-glycoprotein	1.78
Q9HCJ0	TNR6C	Trinucleotide repeat-containing gene 6C protein	1.78
P01008	ANT3	Antithrombin-III	1.77
Q14353	GAMT	Guanidinoacetate N-methyltransferase	1.77
P19652	A1AG2	Alpha-1-acid glycoprotein 2	1.77
Q86X19	TMM17	Transmembrane protein 17	1.75
O76041	NEBL	Nebulette	1.74
Q03167	TGBR3	Transforming growth factor beta receptor type 3	1.70
Q96EX3	WDR34	WD repeat-containing protein 34	1.67
P02792	FRIL	Ferritin light chain	1.66
Q9NWK9	BCD1	Box C/D snoRNA protein 1	1.64
P15559	NQO1	NAD(P)H dehydrogenase [quinone] 1	1.64

Protein ID	Alternative name	Protein name	iTRAQ ratio
		FGGY carbohydrate kinase domain-containing	
Q96C11	FGGY	protein	1.64
Q99598	TSNAX	Translin-associated protein X	1.63
Q9NZM6	PK2L2	Polycystic kidney disease 2-like 2 protein	1.62
P08185	CBG	Corticosteroid-binding globulin	1.62
Q9BXN1	ASPN	Asporin	1.61
Q15063	POSTN	Periostin	1.61
		Double zinc ribbon and ankyrin repeat-containing	
Q9NVP4	DZAN1	protein 1	1.60
Q14651	PLSI	Plastin-1	1.57
P02774	VTDB	Vitamin D-binding protein	1.57
P05543	THBG	Thyroxine-binding globulin	1.57
P25311	ZA2G	Zinc-alpha-2-glycoprotein	1.56
		Diphosphoinositol polyphosphate	
Q9NZJ9	NUDT4	phosphohydrolase 2	1.55
		tRNA (cytosine(34)-C(5))-methyltransferase,	
Q9H649	NSUN3	mitochondrial	1.55
		Phosphatidylinositol-glycan-specific	
P80108	PHLD	phospholipase D	1.55
Q96AB6	NTAN1	Protein N-terminal asparagine amidohydrolase	1.54
Q9H9L4	KANL2	KAT8 regulatory NSL complex subunit 2	1.54
P02647	APOA1	Apolipoprotein A-I	1.53
P48509	CD151	CD151 antigen	1.53
Q9UBW7	ZMYM2	Zinc finger MYM-type protein 2	1.52
Q96LD8	SENp8	Sentrin-specific protease 8	1.52
P35237	SPB6	Serpin B6	1.52
Q5HYK9	ZN667	Zinc finger protein 667	1.51
Q99735	MGST2	Microsomal glutathione S-transferase 2	1.51
Q9NQG6	MID51	Mitochondrial dynamics protein MID51	1.50
Decreased in RIF/Controls			
Q9H9C1	SPE39	Spermatogenesis-defective protein 39 homolog	0.27
		Inositol hexakisphosphate and diphosphoinositol-	
O43314	VIP2	pentakisphosphate kinase 2	0.36
		Tumor necrosis factor receptor superfamily	
P28908	TNR8	member 8	0.40
Q96RD9	FCRL5	Fc receptor-like protein 5	0.44
P62805	H4	Histone H4	0.47
Q9P107	GMIP	GEM-interacting protein	0.48
Q96S82	UBL7	Ubiquitin-like protein 7	0.53

Protein ID	Alternative name	Protein name	iTRAQ ratio
P18124	RL7	60S ribosomal protein L7	0.53
P56202	CATW	Cathepsin W	0.53
Q6P179	ERAP2	Endoplasmic reticulum aminopeptidase 2	0.57
Q05086	UBE3A	Ubiquitin-protein ligase E3A	0.58
P43403	ZAP70	Tyrosine-protein kinase ZAP-70	0.59
P46781	RS9	40S ribosomal protein S9	0.59
Q8TAF3	WDR48	WD repeat-containing protein 48	0.60
		Mitochondrial import receptor subunit TOM5	
Q8N4H5	TOM5	homolog	0.60
P08729	K2C7	Keratin, type II cytoskeletal 7	0.61
Q07020	RL18	60S ribosomal protein L18	0.62
Q9BRX8	F213A	Redox-regulatory protein FAM213A	0.62
P07197	NFM	Neurofilament medium polypeptide	0.62
P15954	COX7C	Cytochrome c oxidase subunit 7C, mitochondrial	0.62
P01861	IGHG4	Immunoglobulin heavy constant gamma 4	0.64
P61313	RL15	60S ribosomal protein L15	0.64
Q96SI1	KCD15	BTB/POZ domain-containing protein KCTD15	0.65
P07196	NFL	Neurofilament light polypeptide	0.65
Q3SX64	OD3L2	Outer dense fiber protein 3-like protein 2	0.65
Q02543	RL18A	60S ribosomal protein L18a	0.65
Q8NGY6	OR6N2	Olfactory receptor 6N2	0.66

Figure 1

The hierarchical clustering for endometrium proteins between repeated implantation failure (RIF) and pregnant controls (Con) groups.

The red color showed the high expression, and the blue color represented the down expression. The color from red to blue represented the ratio from large to small.




Figure 2

GO analysis and String analysis of the set of endometrium proteins biomarker candidates for repeated implantation failure.

(A) GO analysis; (B) The enrichment analysis of GO terms; (C) Molecular function of GO terms; (D) String analysis.







Figure 3

KEGG analysis and EggNOG analysis of the set of endometrium proteins biomarker candidates for repeated implantation failure.

(A) KEGG analysis; (B) The enrichment analysis of KEGG pathways; (C) EggNOG analysis.




Figure 4

Westernblot results of candidate proteins.

GAPDH as internal reference.

